Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with or without platinum-based chemotherapy versus chemotherapy for advanced or metastatic urothelial carcinoma
2015-005731-41Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab, gemcitabine, cisplatin and carboplatin in transitional cell carcinoma (TCC) (3 arms), sponsored by Merck & Co. Primary endpoints: Progression-free survival and Overall survival. Started Aug 2016; status: completed.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2015-005731-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005731-41.